

Effect of a Serotonin Reuptake Inhibitor on Irritability, Apathy, and Psychotic Symptoms in Patients With Alzheimer's Disease

Haroon Siddique, MD; Linda S. Hynan, PhD; and Myron F. Weiner, MD

Objective: To ascertain the impact of treatment with citalopram on irritability, apathy, delusions, and hallucinations in nondepressed behaviorally disturbed Alzheimer's disease (AD) patients.

Method: This was a retrospective analysis of data from the 36-week Clinical Antipsychotic Trials of Intervention Effectiveness in Alzheimer's Disease in which patients with probable AD (diagnosed according to criteria of the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association [NINCDS/ADRDA]) were treated in a naturalistic manner. Scores were compared on the irritability, apathy, delusions, and hallucinations subscales of the Neuropsychiatric Inventory. The trial was conducted between April 2001 and November 2004.

Results: Of the 421 patients enrolled, 44 were started on placebo and were later randomly assigned to citalopram treatment. There were data available for 34 subjects who took placebo for at least 14 days. In this group, there was a 60% reduction in irritability and apathy scores, no effect on scores for delusions, and a clinically insignificant drop in scores for hallucinations.

Conclusions: The use of citalopram was associated with greatly reduced irritability without sedation in a group of behaviorally disturbed patients with AD.

J Clin Psychiatry 2009;70(6):915–918

© Copyright 2009 Physicians Postgraduate Press, Inc.

Received October 27, 2008; accepted February 24, 2009. From the Departments of Psychiatry (all authors), Clinical Sciences, Division of Biostatistics (Dr Hynan), and Neurology (Dr Weiner), University of Texas Southwestern Medical Center, Dallas.

This study was supported by a grant from the National Institutes of Health and the National Institute on Aging (5 P30 AG012300 to Dr Hynan).

The authors report no additional financial or other relationships relevant to the subject of this article.

Corresponding author and reprints: Myron F. Weiner, MD, Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9129 (e-mail: myron.weiner@utsouthwestern.edu).

The management of irritability and other psychiatric symptoms in dementia patients is a significant clinical problem that has not been adequately addressed from the theoretical and practical standpoints. In the realm of aggression and violence, however, there is an extensive literature supporting the role of serotonin deficit.¹ In 1976, Greenberg and Coleman noted that serotonin metabolite 5-hydroxyindole (5-HI) levels in blood were low in hyperactive, institutionalized mentally retarded patients.² In these patients, increasing 5-HI levels in blood to within the normal range by administration of a variety of psychoactive agents was associated with reduced hyperactivity and calming. Patients who remained hyperactive continued to have low 5-HI levels. More recently, serotonin reuptake inhibitors (SRIs) were shown to reduce impulsive aggression in personality-disordered subjects.³

Alzheimer's disease (AD) is associated with an extensive serotonergic deficit⁴ that might partly explain agitation and irritability in this disease; the dorsal raphe nucleus of brain stem, the site of serotonergic forebrain innervation, is markedly depopulated in patients with AD,⁵ and Gottfries et al⁶ found that brain serotonin metabolites are reduced to 30%–40% in AD patients.

At the clinical level, Nyth and Gottfries⁷ reported significantly decreased irritability in 98 nondepressed persons with AD or vascular dementia after treatment with citalopram 20–30 mg/d for 4 weeks. In an open-label study of 16 dementia inpatients with behavioral problems treated with citalopram, disinhibition, agitation, hostility, and suspicion were significantly reduced after 17 days.⁸ The drug was administered at 10 mg/d for the first 72 hours and then at 20 mg/d. A second study by the same investigators found that nondepressed persons with dementia admitted to a psychiatric inpatient unit for management of behavioral symptoms showed a significantly greater effect for citalopram 20 mg/d than for placebo over a period of 17 days.⁹ The outcome data were analyzed using last observation carried forward; about 50% of both groups had dropped out by that time, primarily due to perceived lack of efficacy. In this severely impaired group with mean Mini-Mental State Examination (MMSE)¹⁰ score < 10, citalopram-treated subjects had significantly greater improvement than placebo-treated

subjects on the agitation and lability/tension subscales of the Neuropsychiatric Inventory (NPI),¹¹ but not on the apathy scale.⁹ In a randomized 12-week study comparing citalopram with risperidone in 106 persons with dementia hospitalized for treatment of behavioral problems, both drugs were associated with an approximately one third reduction in a measure of psychotic symptoms; citalopram was associated with a 13% decrease in a measure of agitation as compared with an 8% decrease for risperidone.¹²

A post hoc analysis of a randomized placebo-controlled study of sertraline in donepezil-treated AD patients used a 50% reduction from baseline in behavioral/psychological symptoms as the criterion level of response.¹³ The study found that in AD patients experiencing agitation, irritability, anxiety, aggression, and affective symptoms, sertraline augmentation resulted in a response rate of 60% versus 40% with placebo, using the 4-item NPI behavioral and psychological symptom subscale.

If increasing serotonin levels reduces irritability, it is likely that apathy might also be increased, and a small body of literature suggests that dose-related apathy may occur in persons treated with SRIs for depression.¹⁴ In addition, a retrospective study of 384 elderly depressed psychiatric inpatients treated with selective SRI (SSRI) and non-SSRI drugs showed that a significantly greater proportion of subjects treated with SSRIs remained apathetic at discharge (83.7% of the SSRI group and 73.4% of the non-SSRI group; $P = .029$).¹⁵

We hypothesized that modest doses of a serotonin reuptake-inhibiting drug would decrease irritability in nondepressed AD subjects without significant increase of apathy.

METHOD

Design

This was a retrospective study employing the database of the Clinical Antipsychotic Trials of Intervention Effectiveness in Alzheimer's Disease (CATIE-AD) (conducted between April 2001 and November 2004).¹⁶ The CATIE-AD study was a naturalistic study comparing the SRI citalopram with the antipsychotic drugs risperidone, olanzapine, or quetiapine and with placebo for the treatment of psychosis, aggression, and agitation in persons with probable AD (diagnosed according to criteria of the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association [NINCDS/ADRDA]¹⁷). Subjects were excluded from the study if they were currently or had been treated with 2 of the 3 atypical antipsychotic drugs. A 2-week washout of psychotropic drugs was preferred, but subjects were allowed to continue psychotropic drugs that were thought by the primary care physician to be helpful.

The minimum duration of Phase 1 was 14 days. Phase 2 lasted a minimum of 2 weeks and a maximum of 12 weeks. Phase 1 consisted of randomization to treatment with placebo, risperidone, olanzapine, or quetiapine. Transition from Phase 1 to Phase 2 occurred at variable times at the discretion of the treating physician and was based often on lack of efficacy or undesirable side effects. In Phase 2, subjects were blindly randomly assigned to citalopram, risperidone, olanzapine, or quetiapine. Clinicians had the option of going on to Phase 3, in which they could prescribe open-label risperidone, olanzapine, or quetiapine. The study was approved by the data and safety monitoring board of the National Institute of Mental Health and by each site's institutional review board. Patients or their legally authorized representatives provided written informed consent, as did the caregivers or partners who participated.

We examined data from subjects who were randomly assigned initially to placebo (Phase 1) and subsequently randomly assigned to citalopram 5–30 mg/d (Phase 2), on the basis of the judgment of the treating clinician. We compared the apathy, irritability, delusions, and hallucinations subscale scores of the NPI at the end of the placebo phase (Phase 1) with apathy and irritability scores at the end of the citalopram phase of the study (Phase 2).

The NPI is administered to caregivers to retroactively assess behaviors observed in dementia patients, usually over a period of 1 month, but the observation period for this study was 1 week. The NPI covers 12 domains including delusions, hallucinations, depression/dysphoria, anxiety, agitation/aggression, elation/euphoria, disinhibition, irritability/lability, apathy/indifference, aberrant motor activity, sleep, and appetite and eating disorders. Subscale scores are the product of frequency \times severity scores. Scores for the apathy, irritability, delusions, and hallucinations subscales each range from 0 to 12, with higher scores indicating greater severity.

Subjects were screened for depression using a 21-item version of the Beck Depression Inventory (BDI).¹⁸ Scale scores range from 0 to 63, with higher scores indicating more severe depression. Scores < 10 indicate no or minimal depression.

Statistical Analyses

Baseline median and range is presented for the BDI scores. To examine changes in the NPI total score and the subscale scores (apathy, irritability, delusions, and hallucinations), the last available scores in Phase 1 and Phase 2 for each patient were compared using the Wilcoxon signed rank test. A Spearman rank order correlation was used to compare the duration in Phase 2 with the maximum daily dose of citalopram. The Statistical Package for the Social Sciences (SPSS) software, version 16 (SPSS Inc, Chicago, Illinois), was used for all analyses. Two-sided P values $< .05$ were considered significant.

Table 1. Neuropsychiatric Inventory (NPI) Total Score and Apathy, Irritability, Delusions, and Hallucinations Subscale Scores for Patients With Alzheimer's Disease Who Were Treated With Citalopram (N = 34)

Scale/Time	Median	Minimum	Maximum	Percentile		<i>P</i> Value ^a
				25	75	
Total NPI						.089
End Phase 1	33.00	8	78	29.3	49.0	
End Phase 2	25.00	1	78	16.0	46.5	
Apathy subscale						.099
End Phase 1	5.00	0	12	1.0	8.0	
End Phase 2	2.00	0	12	0.0	6.0	
Irritability subscale						.739
End Phase 1	6.00	0	12	3.0	8.0	
End Phase 2	3.50	0	12	0.0	8.0	
Delusions subscale						.780
End Phase 1	3.50	0	12	0.0	8.0	
End Phase 2	3.50	0	12	0.0	8.0	
Hallucinations subscale						.022
End Phase 1	1.00	0	8	0.0	6.0	
End Phase 2	0.50	0	12	0.0	6.0	

^aWilcoxon signed rank test.

RESULTS

A total of 421 cases were available in the CATIE-AD database. Their demographics are presented elsewhere.¹⁶ The study group for this investigation included the 44 subjects who received placebo as Phase 1 treatment and citalopram as Phase 2 treatment. The NPI scores analyzed represent the last testing performed before the end of each phase or at the last visit of the phase. The first visit for all patients was study day 1. The NPI was administered at weeks 0, 2, 4, 8, 12, 24, and 36; the BDI was administered at weeks 0, 12, 24, and 36. The BDI scores at week 0 ranged from 10 to 20; the median BDI score was 10.

Forty-four patients received placebo in Phase 1 and citalopram in Phase 2. One subject did not have any data for all time points. One patient did not have data available for the end of Phase 1 (placebo) measurement; 8 did not have measurements for the end of Phase 2 (citalopram). For the remaining 34 subjects, the median BDI score at baseline was 10 (range, 0–20). The median duration of Phase 1 was 36 days (range, 14–232 days); the median duration of Phase 2 for the citalopram-treated group was 80 days (range, 14–306 days). The median daily dose of citalopram was 30 mg (range, 10–80 mg). The discontinuation rate for citalopram was 71% (24/34), slightly less than the discontinuation rates for placebo (85%), quetiapine (82%), risperidone (77%), and olanzapine (80%) in Phase 1. Of interest, there was a positive association between citalopram dosage and length of treatment with citalopram ($r = 0.38$, $df = 41$, $P = .015$).

The effects of placebo and citalopram on NPI total scores and scores on the apathy, irritability, delusions, and hallucinations subscales are presented in Table 1.

Although the effect of the drug citalopram on apathy and irritability was not statistically significant, both apathy and irritability scores were reduced by 60%. This finding in behaviorally disturbed nondepressed patients with AD differs from the finding in depressed elders of increased apathy associated with SRI antidepressants (as compared with non-SRIs).¹⁵ We had expected no effect of citalopram on psychotic symptoms, and although there was a significant reduction in the hallucinations subscale of the NPI, these symptoms were of low frequency and intensity, as indicated by a median score of 1 point. There was no effect on delusions.

DISCUSSION

There are a number of confounds in examining the effects of psychotropic medications in the management of behavioral symptoms in dementia, including the placebo response. For example, one third of persons with behavioral problems associated with AD improved on placebo in a 16-week controlled trial.¹⁹ This outcome could also have been attributable to more frequent visits and related support for patient and caregiver. Another, and more likely, explanation is a regression to the mean.²⁰ Dementia-related behaviors tend to be intermittent, differing in this respect from syndromes such as major depressive disorder. Caregivers seek help with dementia-related behaviors when they peak; thus, improvements attributed to medication may equally well be due to the passage of time or greater tolerance of the caregiver for the behavior(s). In this study, the placebo effect was an unlikely cause of improvement in that this was the second phase of the study rather than the initial phase.

CONCLUSIONS

Although it is not clear that the improvement was due to its serotonergic action, use of an SRI was followed by a large decrease in irritability of nondepressed AD patients with a concomitant decrease in apathy. There was no effect on delusions. Although statistically significant, the effect on hallucinations was of unclear clinical significance in view of their low frequency and intensity. Based on these findings—and considering the potential toxicity, side effects, and sedation produced by all antipsychotic agents;²¹ the considerable expense of second-generation antipsychotics; the sedation and ataxia associated with minor tranquilizers; and the relative lack of toxicity and side effects and the low cost of many SRIs—an SRI might be a reasonable first-line treatment of irritability in patients with AD. The positive association between citalopram dose and length of treatment with citalopram suggests that there may be a greater effect with higher doses and that titration to higher than ordinary antidepressant doses may be indicated. This secondary analysis of CATIE-AD data, despite its lack of power and nonsignificant results, nevertheless gives a strong impetus for a larger trial of citalopram and related drugs for irritability in dementia patients.

Drug names: citalopram (Celexa and others), donepezil (Aricept and others), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal and others), sertraline (Zoloft and others).

REFERENCES

1. Siever LJ. Neurobiology of aggression and violence. *Am J Psychiatry*. 2008;165(4):429–442.
2. Greenberg AS, Coleman M. Depressed 5-hydroxyindole associated with hyperactive and aggressive behavior. *Arch Gen Psychiatry*. 1976;33(3):331–336.
3. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. *Arch Gen Psychiatry*. 1997;54(12):1081–1088.
4. Mann DM, Yates PO. Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. *Hum Neurobiol*. 1986;5(3):147–158.
5. Yamamoto T, Hirano A. Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. *Ann Neurol*. 1985;17(6):573–577.
6. Gottfries CG, Adolfsson R, Aquilonius SM, et al. Biochemical changes

in dementia disorders of the Alzheimer's type (AD/SDAT). *Neurobiol Aging*. 1983;4(4):261–271.

7. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multi-center study. *Br J Psychiatry*. 1990;157:894–901.
8. Pollock BG, Mulsant BH. An open pilot study of citalopram for behavioral disturbances of dementia. *Am J Geriatr Psychiatry*. 1997;5(1):70–78.
9. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. *Am J Psychiatry*. 2002;159(3):460–465.
10. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189–198.
11. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology*. 1994;44(12):2308–2314.
12. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. *Am J Geriatr Psychiatry*. 2007;15(11):942–952.
13. Finkel SI, Mintzer JA. Randomized placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestation of Alzheimer's disease in outpatients treated with donepezil. *Int J Geriatr Psychiatry*. 2004;19(1):9–18.
14. Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome. *J Psychiatr Pract*. 2004;10(3):196–199.
15. Wongpakaran N, van Reekum R, Wongpakaran T, et al. Serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. *Ann Gen Psychiatry*. 2007;6:7.
16. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med*. 2006;355(15):1525–1538.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984;34(7):939–944.
18. Beck AT. *Depression Inventory*. San Antonio, TX: The Psychological Corporation; 1987.
19. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in Alzheimer's disease: a randomized placebo-controlled clinical trial. *Neurology*. 2000;55(9):1271–1278.
20. Cummings JL, Tractenberg RE, Gamst A, et al. Regression to the mean: implications for clinical trials of psychotropic agents in dementia. *Curr Alzheimer Res*. 2004;1(4):323–328.
21. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. *J Clin Psychiatry*. 2008;69(6):889–898.

Editor's Note: We encourage authors to submit papers for consideration as a part of our Focus on Alzheimer's Disease and Related Disorders section. Please contact Eric M. Reiman, MD, at ereiman@psychiatrist.com.